Activation Eikon Therapeutics In this young yr he raised one of the largest biotechnological rounds.
Drug startup based in Hayward, California closed almost $ 351 million in the D series from corresponding to such Lux capital AND Alexandria Venture Investments.
The round is the second largest biotechnological startup this yr, only London Verdiva BioAn organization creating the treatment of obesity and cardiometabolic diseases, which in January collected a series A with a value of $ 411 million.
Eikon uses super resolution microscopy to find the effect of drugs on live cells. The company develops therapies for various cancers, including breast, ovary, prostate and melanoma.
Established in 2019, the company has now raised $ 1.1 billion, on Crunchbase.
“Eikon has made extraordinary progress in developing the key stage of the clinical pipeline and the development program at an early stage driven by our uniform molecule tracking technology and the deep knowledge of our multidisciplinary team,” said the president and general director of Dr. Dr. Roger Perlmutter In release. “Thanks to clinical trials currently operating in 28 countries, on 5 continents, we accelerate the development of very necessary therapies, while expanding our research and development possibilities.”
Big money
This is only the latest large round for Eikon, which collected financing of the B series with a value of $ 517.8 million from almost 20 different investors, including funds and accounts really helpful by T. Rowe Price Associatesin 2022
This yr, biotechnological startups have collected almost $ 7 billion in part due to large nine-digit rounds. Last yr, biotechnological startups collected a total of over $ 35 billion.